What happens when we encapsulate a probiotic in an anti-microbial sanitizer? What are the microbial signatures and dermotypes in Atopic Dermatitis? How does the skin microbiome change during ageing over 300 subjects from Europe and Asia? How are CSTs related to intimate area microbiome product development? Since launching the world’s first at home skin Microbiome + Genetics test in 2019, Sequential has been on a path to fully uncover how the microbiome and gene expression signatures relates to skin, scalp, and vaginal microbiome health. Sequential has worked with 60+ clients to support their clinical testing, and help them characterise the effect of their microbiome products on the microbiome in vivo, allowing for rigorous scientific R&D, claims support and substantiation. Please join Oliver’s talk to hear the answers to these questions and other exciting advances in molecular clinical testing.
Sequential is an industry leader in consumer microbiome testing for skin, scalp, and female health. Being named the most significant testing solution in the industry in 2022 and has worked with over 60 clients. Sequential has amassed a valuable dataset of over 30,000 clinical skin samples, 4000 topical ingredients and formulations tested on them, and strain-level quantitative microbiome analysis to fully characterise skin and intimate health.
With Sequential labs in NYC, London and Singapore, they are positioning themselves to be a global leader in the microbiome, mining a growing database for novel biomarkers and actives that will improve human health. Having become profitable in 2023, Sequential is now looking to raise capital to expand to further reduce costs of goods, and scale internationally. They are backed by Corundum Systems Biology, SOSV, Scrum Ventures, Metaplanet Holdings, Enterprise Singapore, Genedant Holdings, Royal Academy of Engineering and Innovate UK.